09Sep 2023
Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction

Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction

The VICTORIA trial findings reveal that vericiguat, a treatment for high-risk heart failure, reduces cardiovascular death and hospitalization due to heart failure. However, its cost-effectiveness hinges on baseline NT-proBNP levels. For patients with lower NT-proBNP levels, vericiguat offers a survival benefit, while those with the highest levels do not benefit significantly. An economic analysis shows vericiguat meets intermediate value criteria but is sensitive to NT-proBNP-related heterogeneity. Cost-effectiveness ratios range from $66,509 to $124,512 per QALY. These results provide critical insights for considering vericiguat in heart failure treatment.

  • #cardiology

Like

Save

Share